These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Medina JA; Rueda A; de Pasos AS; Contreras J; Cobo M; Moreno P; Benavides M; Villanueva A; Alba E Radiother Oncol; 2006 Apr; 79(1):34-8. PubMed ID: 16626826 [TBL] [Abstract][Full Text] [Related]
6. A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract. Foote RL; Kasperbauer JL; Okuno SH; Nichols DA; Olsen KD; Brown PD; Garces YI; Sargent DJ; Strome SE Cancer; 2005 Feb; 103(3):559-68. PubMed ID: 15597408 [TBL] [Abstract][Full Text] [Related]
7. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Lee NY; de Arruda FF; Puri DR; Wolden SL; Narayana A; Mechalakos J; Venkatraman ES; Kraus D; Shaha A; Shah JP; Pfister DG; Zelefsky MJ Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):966-74. PubMed ID: 17145527 [TBL] [Abstract][Full Text] [Related]
8. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity. Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658 [TBL] [Abstract][Full Text] [Related]
9. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870 [TBL] [Abstract][Full Text] [Related]
10. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience. Allal AS; Taussky D; Mach N; Becker M; Bieri S; Dulguerov P Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1431-6. PubMed ID: 15050320 [TBL] [Abstract][Full Text] [Related]
11. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175 [TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. de Arruda FF; Puri DR; Zhung J; Narayana A; Wolden S; Hunt M; Stambuk H; Pfister D; Kraus D; Shaha A; Shah J; Lee NY Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):363-73. PubMed ID: 15925451 [TBL] [Abstract][Full Text] [Related]
13. Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer. Malone JP; Stephens JA; Grecula JC; Rhoades CA; Ghaheri BA; Schuller DE Head Neck; 2004 Jul; 26(7):561-72. PubMed ID: 15229898 [TBL] [Abstract][Full Text] [Related]
14. Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck--a phase III trial from a single institution in India. Ghoshal S; Goda JS; Mallick I; Kehwar TS; Sharma SC Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):212-20. PubMed ID: 18343310 [TBL] [Abstract][Full Text] [Related]
15. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857 [TBL] [Abstract][Full Text] [Related]
17. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161 [TBL] [Abstract][Full Text] [Related]
18. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis. Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114 [TBL] [Abstract][Full Text] [Related]
19. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma. Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823 [TBL] [Abstract][Full Text] [Related]
20. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]